AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)
May 19 2021 - 7:30AM
AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”),
a clinical stage biopharmaceutical company specializing in the
development of targeted, non-systemic therapies for
gastrointestinal (GI) diseases, today announced that James
Sapirstein, AzurRx President, CEO and Chairman, will present at the
Rocky Mountain Microcap Conference on May 26, 2021.
During his live virtual presentation on Wednesday, May 26, 2021
at 12:28 p.m. EDT, Mr. Sapirstein will provide an overview of
AzurRx’s business and clinical development programs and discuss
anticipated 2021 and early 2022 milestones. Additionally, Mr.
Sapirstein and members of the AzurRx management team will be
participating in virtual one-on-one meetings with registered
investors.
Details of the presentation are as follows:
|
Event: |
|
Rocky Mountain Microcap Conference |
|
Date: |
|
Wednesday, May 26, 2021 |
|
Time: |
|
12:28 p.m. EDT |
|
Registration to View
Virtual Presentation: |
|
https://rockymountain.mysequire.com/ |
About AzurRx BioPharma, Inc.AzurRx BioPharma,
Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company
specializing in the development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases. The Company has a pipeline of
three gut-restricted GI assets. The lead therapeutic candidate is
MS1819, a recombinant lipase for the treatment of exocrine
pancreatic insufficiency (EPI) in patients with cystic fibrosis and
chronic pancreatitis, currently in two Phase 2 clinical trials.
AzurRx is launching two clinical programs using proprietary
formulations of niclosamide, a pro-inflammatory pathway inhibitor,
FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and
diarrhea in oncology patients and FW-1022, for COVID-19
gastrointestinal infections. The Company is headquartered in Delray
Beach, Florida with clinical operations in Hayward, California. For
more information, visit www.azurrx.com.
Forward-Looking StatementThis press release may
contain certain statements relating to future results which are
forward-looking statements. It is possible that the Company’s
actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in these forward-looking statements, depending on factors
including whether results obtained in preclinical and nonclinical
studies and clinical trials will be indicative of results obtained
in future clinical trials; whether preliminary or interim results
from a clinical trial will be indicative of the final results of
the trial; the size of the potential markets for the Company’s drug
candidates and its ability to service those markets; and the
Company’s current and future capital requirements and its ability
to raise additional funds to satisfy its capital needs. Additional
information concerning the Company and its business, including a
discussion of factors that could materially affect the Company’s
financial results are contained in the Company’s Annual Report on
Form 10-K for the year ended December 31, 2020 under the heading
“Risk Factors,” as well as the Company’s subsequent filings with
the Securities and Exchange Commission. All forward-looking
statements included in this press release are made only as of the
date of this press release, and we do not undertake any obligation
to publicly update or correct any forward-looking statements to
reflect events or circumstances that subsequently occur or of which
we hereafter become aware.
For more information:AzurRx BioPharma, Inc.1615
South Congress AvenueSuite 103Delray Beach, Florida 33445Phone:
(646) 699-7855info@azurrx.com
Media contact:Tiberend Strategic Advisors,
Inc.Johanna Bennett/Ingrid Mezo(212) 375-2665/(646)
604-5150jbennett@tiberend.com / imezo@tiberend.com
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Sep 2023 to Sep 2024